MSDC Presents Phase 2a Clinical Trial Results at the 14th International Conference on Alzheimer’s Drug Discovery

 KALAMAZOO, Mich., /Sept. 9, 2013 – Metabolic Solutions Development Company, LLC (MSDC) has announced that Jerry Colca, PhD, co-founder and chief scientific officer of MSDC, will present results of a Phase 2a study on September 9 at the 14th International Conference on Alzheimer’s Drug Discovery. In people with dementia due to Alzheimer’s disease (AD) who were not diabetic, the study found that the mTOT™-modulating insulin sensitizer (MSDC-0160) maintained glucose metabolism in key regions of the brain associated with cognitive decline due to AD, as confirmed by FDG-PET imaging…

PDF: MSDC Presents Phase 2a Clinical Trial Results at the 14th International Conference on Alzheimers Drug Discovery